Cuihong Wei
YOU?
Author Swipe
View article: Uncommon Evolution From Acute Myeloid Leukaemia to <i>JAK2</i> ‐Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From <i>TET2</i> / <i>SRSF2</i> ‐Mutated Haematopoietic Progenitors
Uncommon Evolution From Acute Myeloid Leukaemia to <i>JAK2</i> ‐Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From <i>TET2</i> / <i>SRSF2</i> ‐Mutated Haematopoietic Progenitors Open
Background The emergence of JAK2 ‐mutated myeloproliferative neoplasms (MPNs) after remission from acute myeloid leukaemia (AML) is exceedingly rare. Case Description This case series describes two patients who developed JAK2 ‐mutated MPNs…
View article: Invasive Melanoma Arising in a <scp>BAP1</scp>‐Inactivated Melanocytic Tumor With <i>NRAS</i> Mutation: A Report of Exceptional Case With Emphasis on Its Genomic Features and Review of the Literature
Invasive Melanoma Arising in a <span>BAP1</span>‐Inactivated Melanocytic Tumor With <i>NRAS</i> Mutation: A Report of Exceptional Case With Emphasis on Its Genomic Features and Review of the Literature Open
BAP1‐inactivated melanocytic tumor is a distinct entity with loss of BAP1 protein and epithelioid morphology. It shares histopathologic features with Spitz nevus and nevoid melanoma, and it can occur sporadically or with germline BAP1 pred…
View article: Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype
Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype Open
The biology of Monosomal Karyotype Acute Myeloid Leukemia (MK AML) remains unclear, and its mutational profile has not been exclusively assessed. We sought to determine the genomic profile of MK AML patients and its correlation with overal…
View article: Expanding the spectrum of AFF2 carcinoma: clinical, morphological, immunohistochemical, and molecular characteristics of five cases harboring alternate fusions
Expanding the spectrum of AFF2 carcinoma: clinical, morphological, immunohistochemical, and molecular characteristics of five cases harboring alternate fusions Open
In recent years, multiple molecularly defined entities have emerged in head and neck pathology, especially among sinonasal squamous and basaloid carcinomas, including NUT carcinoma, SWI/SNF-deficient carcinoma, and DEK :: AFF2 carcinoma. T…
View article: Genetic Landscape and Risk Stratification of <scp>AML</scp> With Hyperdiploid Karyotype
Genetic Landscape and Risk Stratification of <span>AML</span> With Hyperdiploid Karyotype Open
Hyperdiploid karyotype (HK) (49–65 chromosomes) in acute myeloid leukemia (AML) is rare. Recently, HK‐AML with only numerical changes has been reclassified into an intermediate risk group in the updated 2022 European LeukemiaNet (ELN) risk…
View article: Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort
Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort Open
Background/Objectives: The 2022 European LeukemiaNet (ELN 2022) is a widely used genotypic risk classification tool for the treatment and prognostication of acute myeloid leukemia (AML) patients. Our study evaluates its effectiveness in ca…
View article: A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria
A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria Open
The proposed fifth edition of the World Health Organization classification of hematolymphoid tumors (WHO-HAEM5) and International Consensus Classification (ICC) provide different definitions of acute myeloid leukemia with myelodysplasia-re…
View article: Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer Open
In advanced non-small cell lung cancer (NSCLC), patients with actionable genomic alterations may derive additional clinical benefit from targeted treatment compared to cytotoxic chemotherapy. Current guidelines recommend extensive testing …
View article: Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry
Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry Open
Background Acute promyelocytic leukemia (APL) is one of the most life‐threatening hematological emergencies and requires a prompt correct diagnosis by cytomorphology and flow cytometry (FCM) with later confirmation by cytogenetics/molecula…
View article: Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia Open
Core-binding factor acute myeloid leukemia is characterized by t(8;21) or inv(16) and the fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11. International guidelines recommend monitoring for measurable residual disease every 3 months for 2 year…